FDA backs new acne application ‘Fabior Foam’
Stiefel Labratories is the company behind ‘Fabior Foam’, a topical application comprised of the compound tazarotene, a member of the acetylenic class of retinoids said to tackle the most common skin problem in the US, affecting about 40 – 50 million Americans at any one time.
"We believe Fabior Foam will be an important treatment option for people with moderate-to-severe acne," said vice president, Jean-Christophe May, North America Dermatology.
According to the company, which is a part of the GSK group, the FDA approval has been based on two multi-center, randomized, double-blind, vehicle-controlled pivotal Phase 3 studies conducted in the US and Canada.
Trials
Stiefel reports that topical appications carried out on 744 patients aged between 12 and 45 years of age with acne vulgaris once daily for twelve weeks, found only 1 percent of patients reporting adverse reactions to Fabior Foam. "Most adverse reactions were mild to moderate in severity."
Other skin care applications
Last year, the cosmetics player launched an anti-aging product, Revaleskin Hydraskin Complex from CoffeeBerry polyphenol antioxidants.
Then, the complex had been developed to help fight oxidative damage, one of the leading causes of skin cell depletion, something that had been scientifically proven to be a primary contributor to premature skin aging.
The CoffeeBerry Exract was developed from the berry of the African Coffea Arabica plant, which is known for its enhanced anti-oxidant properties. The extract is actually derived from the coffee cherry, which is also used as food.
The company claims to be one of the only cosmetics players in the world to use this fruit as an extract, and says that it provides particularly effective anti-aging properties due to the fact that it contains a higher level of polyphenol anti-oxidants than many other leading sources, including pomegranate and green tea.
